Literature DB >> 23266944

Neurodevelopmental disabilities in children with intermediate and premutation range fragile X cytosine-guanine-guanine expansions.

Meredith M Renda1, Robert G Voigt, Dusica Babovic-Vuksanovic, W Edward Highsmith, Sherry S Vinson, Christine M Sadowski, Randi J Hagerman.   

Abstract

To determine the range of neurodevelopmental diagnoses associated with intermediate (45-54 repeats) and premutation (55-200 repeats) range cytosine-guanine-guanine fragile X expansions, the medical records of children with intermediate or premutation range expansions were retrospectively reviewed, and all neurodevelopmental diagnoses were abstracted. Twenty-nine children (9 female, 20 male; age, 13 months to 17 years) with intermediate (n = 25) or premutation (n = 4) range expansions were identified with neurodevelopmental diagnoses, including global developmental delay/intellectual disability (n = 15), language and learning disorders (n = 9), attention-deficit hyperactivity disorder (n = 5), epilepsy (n = 5), and motor disorders (n = 12), including 2 boys younger than 4 years of age with tremor and ataxia. Thus, children with intermediate or premutation range fragile X cytosine-guanine-guanine expansions may be more susceptible than children without such expansions to other processes, both genetic and environmental, that contribute to neurodevelopmental disability.

Entities:  

Keywords:  developmental disability; fragile X syndrome; premutation

Mesh:

Substances:

Year:  2012        PMID: 23266944     DOI: 10.1177/0883073812469723

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  8 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

Review 2.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

3.  Climbing the branches of a family tree: diagnosis of fragile X syndrome.

Authors:  Jeannie Visootsak; Heather Hipp; Heather Clark; Elizabeth Berry-Kravis; Tovi Anderson; Dawn Laney
Journal:  J Pediatr       Date:  2014-03-06       Impact factor: 4.406

Review 4.  Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families.

Authors:  Anne Wheeler; Melissa Raspa; Randi Hagerman; Marsha Mailick; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

5.  Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series.

Authors:  Sarah M Debrey; Maureen A Leehey; Olga Klepitskaya; Christopher M Filley; Raj C Shah; Benzi Kluger; Elizabeth Berry-Kravis; Elaine Spector; Flora Tassone; Deborah A Hall
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

6.  Transcription-associated R-loop formation across the human FMR1 CGG-repeat region.

Authors:  Erick W Loomis; Lionel A Sanz; Frédéric Chédin; Paul J Hagerman
Journal:  PLoS Genet       Date:  2014-04-17       Impact factor: 5.917

7.  Developmental profiles of infants with an FMR1 premutation.

Authors:  Anne C Wheeler; John Sideris; Randi Hagerman; Elizabeth Berry-Kravis; Flora Tassone; Donald B Bailey
Journal:  J Neurodev Disord       Date:  2016-11-03       Impact factor: 4.025

8.  Cascade Testing for Fragile X Syndrome in a Rural Setting in Cameroon (Sub-Saharan Africa).

Authors:  Karen Kengne Kamga; Séraphin Nguefack; Khuthala Minka; Edmond Wonkam Tingang; Alina Esterhuizen; Syntia Nchangwi Munung; Jantina De Vries; Ambroise Wonkam
Journal:  Genes (Basel)       Date:  2020-01-28       Impact factor: 4.141

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.